3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
3
Terminated
2
Completed
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
8
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Fallopian Tube Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
490
Carboplatin
436
Gemcitabine
394
Docetaxel
385
Cisplatin
360
pembrolizumab
344
Bevacizumab
335
Nivolumab
261
Pemetrexed
243
Capecitabine
221
Dexamethasone
213
Fluorouracil
211
Rituximab
203
Trastuzumab
193
Cyclophosphamide
190
Oxaliplatin
160
Erlotinib Hydrochloride
147
Ipilimumab
145
atezolizumab
144
Prednisone
144
Cetuximab
142
Irinotecan
139
Leucovorin
130
Doxorubicin
130
Sorafenib
120
Lenalidomide
119
Bortezomib
118
Sunitinib
107
Everolimus
93
130-nm albumin-bound paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled